Description
& EXPERIENCE and other key HTA countries and communicated with payers or relevant HTA review organizations for Xtandi (enzalutamide) Myrbetriq (mirabegron) Vesicare (solifenacin) Prograf (tacrolimus) and Advagraf (tacrolimus extended release) I supported oncology urology and immunology therapeutic areas by providing expertise and generate clinical and economic data to support the medical value of Astellas products * I developed and oversaw health economic comparative effectiveness real-world evidence (RWE) patient reported outcomes (PRO) and epidemiological research activities in support of Xtandi Myrbetriq Vesicare Prograf and Advagraf as per the Medical Affairs Strategic Plan * I communicated with internal stakeholders to understand and support the HECOR needs of the business and collaborate with external stakeholders & HECOR experts * I was committed to actively participate at the Medical Affairs Leadership Team I provided oversight and input for HECOR projects/initiatives protocol development regulatory documents scientific publications and independent research proposals for both in-line and development products * I extensively contributed to the development of health economic gap analysis assessment * I effectively worked with internal and external stakeholders to develop clinically meaningful quality controls performance metrics outcome assessments analysis plans and publications relevant to HECOR data generation activities and ensure all projects are in compliance with all internal and external regulations * I successfully represented Astellas at regional and national forums conferences and professional associations * I had a strategic collaborations with global colleagues to advance HECOR initiatives globally * I extensively collaborated with global stakeholders to support and develop Global Value Dossier to maximize commercial opportunities for Astellas products I effectively applied my in-depth understanding of the healthcare system and reimbursement requirements from Canada and other key HTA countries and communicated them with our payers or relevant HTA review organizations to generate evidences for Votrient (pazopanib) Tykerb (lapatinib) and Arzerra (Ofatumumab) in oncology and NUCALA (mepolizumab) Breo Ellipta (Fluticasone + Vilanterol) and Arnuity (Fluticasone Furate) in Asthma * I extensively contributed to the development of the Canadian reimbursement and access plan for Votrient Tykerb Arzerra NUCALA Breo Ellipta and Arnuity aligned with GSK global medical and commercial strategy plan in order to help secure reimbursement market access/formulary listing and promotion and optimal pricing * I heavily contributed to the development of the Canadian health economic strategies and oversaw the implamentation of those to support the overall reimbursement and market access strategies and the value propositions of my assets. * I extensively collaborated cross-functionally with internal stakeholders to support and develop health economic tools and summaries and ensures information was utilized effectively * I Led the design of economic models and Budget Impact Models to demonstrate the economic and humanistic benefits of my assets in a rigorous and timely manner * I developed and oversaw the conduct of budget impact analyses and burden of illness analysis as needed * I directed and oversaw the data analyses and reported of the relevant health economics & outcomes research studies and lead the publication and presentation of data intenally and externally in different national and international conferences. * I extensively provided input into global health economics and outcomes research studies * I effectvely recruited and managed investigators/vendors to conduct health economics and outcomes research studies * I heavily collaborated with local and global matrix teams to develop Value Dossier at earlier stage of in-line and pipeline drugs * I developed and maintained excellent working relations with external HO/payer experts/thought leaders * I effectvely managed external consultants/Clinical Research Organizations/third parties to achieve project objectives within time lines and within budget * I mentored two PhD students for their projects May Post-doctoral pharmacoepidemiology Sainte-Justine Hospital Univ of Montreal Montreal Quebec Canada I collaboratively designed conducted a 6-month randomized clinical trials on " Effect of testosterone supplementation therapy on Cognition Sexual Functioning and serum C-reactive protein in Aging Dutch Men * I designed and analyzed several observation studies in cardiovascular endocrinology diabetes rheumatology and psychiatry fields (listed in publication section)
Accomplishments
Highlights:
Keywords
